109912-36-9

Upstream product

• 109912-28-9 N-(4-methoxybenzyl)-N-2-pyridinyl-1,2-ethanediamine 
• 74764-17-3 2-[(pyridin-2-yl)amino]ethylamine 
• 109-04-6 2-bromo-pyridine 
• 562847-50-1 2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-N-{2-[(4-methoxy-benzyl)-pyridin-2-yl-amino]-ethyl}-N-methyl-acetamide 
• 104499-47-0 N-Desmethylpyrilamine 
• 52818-63-0 2-(4-methoxybenzylamino)pyridine 
• 562847-54-5 2-amino-N-{2-[(4-methoxy-benzyl)-pyridin-2-yl-amino]-ethyl}-N-methyl-acetamide 
• 562847-59-0 ({2-[(4-methoxy-benzyl)-pyridin-2-yl-amino]-ethyl}-methyl-amino)-acetonitrile 

Downstream Products

• 149841-65-6 N-[2-[N-[2-[N-(4-methoxybenzyl)-N-(pyridin-2-yl)amino]ethyl]-N-methylamino]ethyl]-N'-[3-[3-(piperidinomethyl)phenoxy]propyl]urea 
• 149841-76-9 N-cyano-N'-[2-[[(2-guanidino-4-thiazolyl)methyl]thio]ethyl]-N''-[2-[N-[2-[N-(4-methoxybenzyl)-N-(2-pyridyl)amino]ethyl]-N-methylamino]ethyl]guanidine 

Relevant academic research and scientific papers

Synthesis and dual histamine H1 and H2 receptor antagonist activity of cyanoguanidine derivatives

Premedication with a combination of histamine H1 receptor (H1R) and H2 receptor (H2R) antagonists has been suggested as a prophylactic principle, for instance, in anaesthesia and surgery. Aiming at pharmacological hybrids combining H1R and H2R antagonistic activity, a series of cyanoguanidines 14-35 was synthesized by linking mepyramine-type H1R antagonist substructures with roxatidine-, tiotidine-, or ranitidine-type H2R antagonist moieties. N-desmethylmepyramine was connected via a poly-methylene spacer to a cyanoguanidine group as the "urea equivalent" of the H2R antagonist moiety. The title compounds were screened for histamine antagonistic activity at the isolated ileum (H1R) and the isolated spontaneously beating right atrium (H2R) of the guinea pig. The results indicate that, depending on the nature of the H2R antagonist partial structure, the highest H1R antagonist potency resided in roxatidine-type compounds with spacers of six methylene groups in length (compound 21), and tiotidine-type compounds irrespective of the alkyl chain length (compounds 28, 32, 33), N-cyano-N'-[2-[[(2- guanidino-4-thiazolyl)methyl] thio]ethyl]-N″-[2-[N-[2-[N-(4-methoxybenzyl)-N-(pyridyl)-amino] ethyl]-N-methylamino]ethyl] guanidine (25, pKB values: 8.05 (H1R, ileum) and 7.73 (H2R, atrium) and the homologue with the mepyramine moiety connected by a six-membered chain to the tiotidine-like partial structure (compound 32, pKB values: 8.61 (H1R) and 6.61 (H2R) were among the most potent hybrid compounds. With respect to the development of a potential pharmacotherapeutic agent, structural optimization seems possible through selection of other H1R and H2R pharmacophoric moieties with mutually affinity-enhancing properties.

Synthesis and pharmacological activity of fluorescent histamine H1 receptor antagonists related to mepyramine

Fluorescently labeled histamine H1 receptor antagonists were synthesized starting from N-demethylmepyramine by introduction of ω-aminoalkyl chains (2-8 methylene groups in length) followed by derivatization of the terminal NH2 group with various fluorophores (fluorescein, naphthofluorescein, rhodamine, tetramethylrhodamine, BODIPY, dansyl, and nitrobenzoxadiazole (NBD)). On the isolated guinea pig ileum and in a Ca2+ assay on U373MG human glioblastoma cells the highest H1 antagonistic activities were found in 5- and 6-carboxyfluorescein labeled compounds with hexa- and octamethylene spacers and in an analogous NBD-aminohexanoyl derivative (pA2 or pKB values in the range: 8.3-9.0; compared to 9.3-9.4 for mepyramine).